In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberizing the Rep: Can E-Marketing Solve Pharma's Promotional Dilemma?

Executive Summary

Drug marketing is increasingly expensive and decreasingly productive. WebMD Health, the dominant health portal, argues it is not merely another advertising forum, but a more effective influencer of consumer and physician behavior than detail reps and DTC promotion. So far, drug companies remain on the sidelines, having been burned once by similar arguments about the marketing value of neutral channels, represented by PBMs, of which many of WebMD's managers are alumnae.

You may also be interested in...



The Vioxx Withdrawal: Can the Industry Avoid the Whirlpool?

The Vioxx withdrawal is one of those seminal events that, because of the players involved--the industry's largest companies, some of their most valuable drugs, both the European and American regulatory structures--holds up a mirror to an entire industry. Given the record breaking valuation slides, the market is taking a very critical look at the industry's strategies; so should the people who run it.

Activating Consumers

A new survey shows top drug executives still question their ability to exploit consumer promotion. They've got good reason: while consumer promotion clearly works in driving patients to doctors, increasing diagnosis rates and increasing patient requests for specific products, large numbers of their switch requests are denied. To give consumers sufficient power to influence their physician's prescribing behavior--Effective Voice-companies need a deeper understanding of physician attitudes towards requests in general, the specific therapeutic area and the product vis-à-vis competition.

Belief-Based Marketing: Anticipating, Not Just Analyzing Behavior

In pharmaceutical marketing, three industry/structural conditions have combined so that companies compete by outspending: the R&D monotony of chasing after the same targets in the same markets; monotony of information--using the same market and customer information to make identical prioritization decisions; and application monotony, in which regulatory oversight, consumer privacy issues and established industry practice cause marketers to create similar commercial programs against the same targets. Marketers can outsmart, rather than outspend, by exploiting the belief structures of physician or consumer targets, to develop differentially targeted and segment-tailored campaigns that greatly enhance ROI.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel